medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2015; 14 (1)


Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C

Martínez-Macías RF, Cordero-Pérez P, Juárez-Rodríguez OA, Chen-López CY, Martínez-Carrillo FM, Alarcón-Galván G, Mercado-Hernández R, Muñoz-Espinosa LE

Idioma: Ingles.
Referencias bibliográficas: 33
Paginas: 36-45
Archivo PDF: 140.61 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Szabo SM, Bibby M, Yuan Y, Donato BM, Jimenez-Mendez R, Castaneda-Hernandez G, Rodíguez-Torres M, et al. The epidemiologic burden of hepatitis C virus infection in Latin America. Ann Hepatol 2012; 11: 623-35.

  2. Van Der Meer A, Velt B, Feld JJ, Wedemeyer H, Dfour J-F, Lammert F, Duarte-Rojo A, et al. Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. JAMA 2012; 308: 2584-93.

  3. Yu M, Lin S-M, Chuang W-L, Dai C-Y, Wang J-H, Lu S-N, Sheen IS, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antiviral therapy 2006; 11: 985-94.

  4. Gomez EV, Rodriguez YS, Bertot LC, Gonzalez AT, Perez YM, Soler EA, García AY, et al. The natural history of compensated HCV-related cirrhosis: A prospective long-term study. J Hepatol 2012; 58: 434-44.

  5. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, Ascione A, et al. Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007; 45: 579-87.

  6. Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, Suzuki F, et al. Natural History of Compensated Cirrhosis in the Child-Pugh Class A Compared Between 490 Patients With Hepatitis C and 167 With B Virus Infections. J Med Virol 2006; 78: 459-65.

  7. Reggiardo MV, Fay F, Tanno M, García-Camacho G, Bottaso O, Ferretti S, Godoy A, et al. Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects. Ann Hepatol 2012; 11: 658-66.

  8. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.

  9. Ghany MG, Strader DB. Diagnosis, Management, and Treatment of Hepatitis C: An Update. Hepatology 2009; 49: 1335-74.

  10. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009; 50: 387-92.

  11. Méndez-Sánchez N, García-Villegas E, Merino-Zeferino B, Ochoa-Cruz S, Villa AR, Madrigal H, Kobashi-Margáin RA, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol 2010; 9: 428-38.

  12. Méndez-Sánchez N. The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico. Ann Hepatol 2012; 11: 550-51.

  13. Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver International 2011; 31: 18-29.

  14. Pawlotsky J-M. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-S73.

  15. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.

  16. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008; 48: S68-S92.

  17. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004; 10: S115-S120.

  18. Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 1651-3.

  19. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46: 922-38.

  20. Bajaj J. Review article: the modern management of hepatic encephalopathy. Alimentary pharmacology & therapeutics 2010; 31: 537-47.

  21. Third Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106: 3143.

  22. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Hepatology 2012; 55: 2005-23.

  23. Sullivan KM, Pezullo JC. Single Person-Time Rate. Available at: http://www.openepi.com/PersonTime1/PersonTime1. htm. 2013.

  24. Brenn T, Arnesen E. Selecting risk factors: a comparison of discriminant analysis, logistic regression and Cox’s regression model using data from the Tromsø heart study. Statistics in medicine 1985; 4: 413-23.

  25. Johnson RA, Wichern DW. Applied Multivariate Statistical Analysis. Prentice Hall; 2002.

  26. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, et al. Prognosis of Chronic Hepatitis C: Results of a Large, Prospective Cohort Study. Hepatology 1998; 28: 1687-95.

  27. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.

  28. Brunetto M, Oliveri F, Koehler M, Zahm F, Bonino F. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-9. 45 Chronic hepatitis C events in Mexicans. , 2015; 14 (1): 36-45

  29. Di Benedetto N, Peralta M, Alvarez E, Schroder MT, Estepo C, Paz S, Fainboim, et al. Incidence of hepatocellular carcinoma in hepatitis C cirrhotic patients with and without HIV infection: a cohort study, 1999-2011. Ann Hepatol 2014; 13: 38-44.

  30. Ferreira SdC, Carneiro MdV, Souza FF, Teixeira AC, Villanova MG, de Castro Figueiredo JF, Passos AD, et al. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon. Braz J Infect Dis 2010; 14: 330-4.

  31. Hsu C-S, Huang C-J, Kao J-H, Lin HH, Chao Y-C, Fan Y-C, Pei-Shan Tsai. Interferon-Based Therapy Decreases Risks of Hepatocellular Carcinoma and Complications of Cirrhosis in Chronic Hepatitis C Patients. PLoS One 2013: 8: e70458.

  32. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim H-Y, Seeff LB, et al. A Prospective Study of the Rate of Progression in Compensated, Histologically Advanced Chronic Hepatitis C. Hepatology 2011; 54: 396-405.

  33. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Int Med 1999; 131: 174-81.




2020     |     www.medigraphic.com